neiratax
as kalceks - piridoksino hidrochloridas/tiamino hidrochloridas/cianokobalaminas/lidokaino hidrochloridas - injekcinis tirpalas - 100 mg/100 mg/1 mg/20 mg/2 ml - vitamin b1 in combination with vitamin b6 and/or vitamin b12
neuromultivit
g.l. pharma gmbh - tiamino hidrochloridas/piridoksino hidrochloridas/cianokobalaminas - plėvele dengtos tabletės - 100 mg/200 mg/0,2 mg - vitamin b1 in combination with vitamin b6 and/or vitamin b12
neurorubine
teva b.v. - tiamino hidrochloridas/piridoksino hidrochloridas/cianokobalaminas - injekcinis tirpalas - 100 mg/100 mg/1 mg/3 ml - vitamin b1 in combination with vitamin b6 and/or vitamin b12
anoveb
sia ingen pharma - tiamino hidrochloridas/piridoksino hidrochloridas/cianokobalaminas - injekcinis tirpalas - 100 mg/100 mg/1 mg/2 ml - vitamin b1 in combination with vitamin b6 and/or vitamin b12
altargo
glaxo group ltd - retapamulinas - impetigo; staphylococcal skin infections - antibiotikai ir chemoterapiniai preparatai dermatologiniam naudojimui - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. Žr. skirsnius 4. 4 ir 5. 1 svarbi informacija apie klinikinius veiklos retapamulin nuo įvairių rūšių staphylococcus aureus. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
ceprotin
takeda manufacturing austria ag - žmogaus proteinas c - purpura fulminans; protein c deficiency - antitromboziniai vaistai - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.
faslodex
astrazeneca ab - fulvestrantas - krūties navikai - endokrininės terapija, anti-estrogenai - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - arba perimenopausal moterys, derinant gydymą su palbociclib turėtų būti kartu su liuteinizuojančio hormono atpalaiduojantis hormonas (lhrh) agonistas.
gliolan
photonamic gmbh & co. kg - 5-aminolevulino rūgšties hidrochloridas - glioma - antinavikiniai vaistai - gliolan skiriamas suaugusiems pacientams, kad būtų galima vizualizuoti piktybinius audinius piktybinės gliomos chirurgijos metu (iii ir iv kategorijos pasaulio sveikatos organizacija).
bluevac btv (previously known as bluevac btv8)
cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - imunologiniai preparatai - sheep; cattle - sheepactive vakcinacijos nuo mėlynojo liežuvio ligos viruso serotipas 8 išvengti viraemia ir sumažinti klinikinius požymius. imuniteto pradžia: 20 dienų po antrosios dozės. imuniteto trukmė: 1 metai po antrosios dozės. cattleactive vakcinacijos nuo mėlynojo liežuvio ligos viruso serotipas 8 išvengti viraemia. imuniteto atsiradimas: 31 diena po antrosios dozės. imuniteto trukmė: 1 metai po antrosios dozės.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.